Search Medical Condition
Please enter condition
Please choose location

Seminole, Florida Clinical Trials

A listing of Seminole, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (187) clinical trials

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with ...

Phase

0.0 miles

Learn More »

A phase 3 research study of an oral investigational medication as induction and maintenance therapy for adults ages 18 to 75 with moderate to severe ulcerative colitis. Note, study participants may receive the investigational medication or placebo. For more information, please visit our study website at: www.TrueNorthStudy.com

Phase

2.21 miles

Learn More »

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

The primary objective is to assess the safety and tolerability of AR101 when used in a CODIT™ regimen for approximately 6 months in peanut-allergic children.

Phase

2.62 miles

Learn More »

Study of the Efficacy Safety and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of refractory chronic cough

Phase

2.62 miles

Learn More »

Safety and Efficacy of KPI-12 in Subjects With Dry Eye Disease

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.

Phase

3.46 miles

Learn More »

Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease

This is a Phase 3, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and efficacy of KPI-121 0.25% ophthalmic suspension versus vehicle in subjects with dry eye disease.

Phase

3.46 miles

Learn More »

A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study

Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss. This study is being conducted ...

Phase

3.46 miles

Learn More »

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

This two-part, part 1: open-label extension (OLE) and part 2: safety monitoring (SM) study will examine the efficacy and safety of continued etrolizumab treatment in moderate to severe ulcerative colitis (UC) participants previously enrolled in etrolizumab Phase II/III studies. Participants with moderate to severe UC who were enrolled in the ...

Phase

4.03 miles

Learn More »

A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)

This Phase III, double blind, placebo and active comparator controlled, multicenter study will investigate the efficacy and safety of etrolizumab in induction of remission in participants with moderately to severely active UC who are naïve to TNF inhibitors and refractory to or intolerant of prior immunosuppressant and/or corticosteroid treatment.

Phase

4.03 miles

Learn More »

One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease

RECD3125 is a double-blind, placebo-controlled, parallel-group, multicenter, multiregional, 52-week study to assess the efficacy and safety of rifaximin DR tablets for the induction of clinical remission and endoscopic response at 16 weeks followed by clinical and endoscopic remission after 52 weeks of continuous therapy in subjects with active moderate Crohn's ...

Phase

4.03 miles

Learn More »